Skip to main content

Table 1 Sample Characteristics

From: A pilot open series of lamotrigine in DBT-treated eating disorders characterized by significant affective dysregulation and poor impulse control

ID

Age

Ethnicity

Race

BMI (kg/m2)

Diagnosis at Admission

Days on Lamotrigine at Baseline Assessment

Total Days on Lamotrigine

Final Lamotrigine Dose (mg/day)

Concurrent Medications

1

28

Non-Hispanic

Black

26.3

EDNOSa

−2

223

150

quetiapine XR, bupropion XL, levomilnacipran

2

23

Non-Hispanic

White

20.2

EDNOSb

−5

246

200

duloxetine, trazodone

3

41

Non-Hispanic

White

21.9

EDNOSc

−4

253

100

escitalopram

4

42

Hispanic

Other

28.3

BN

1

190

100

venlafaxine XR, naltrexone

5

18

Non-Hispanic

White

19.7

AN-BP

1

86

200

sertraline, gabapentin

6

31

Non-Hispanic

White

20.1

AN-BP

1

85

200

gabapentin, naltrexone

7

25

Non-Hispanic

White

19.1

AN-R

0

102

200

duloxetine, sertralined

8

31

Hispanic

Other

22.3

AN-BP

0

71

100

fluoxetine

9

32

Non-Hispanic

Other

25.7

BN

1

71

200

duloxetine

  1. aHigh-normal to mildly overweight with restrictive eating and purging; bMildly underweight AN with alternating severe restrictive eating, bingeing, and occasional purging; cLifetime history of mostly BN with episodes of AN-BP. During period of study, most characteristic of low-normal-weight AN-P; dDuloxetine was concurrent with lamotrigine for one month and was subsequently replaced with sertraline in the second month. In the third month, lamotrigine was the only medication prescribed. BMI = body mass index; AN-BP = anorexia nervosa, binge-eating/purging subtype; EDNOS = eating disorder not otherwise specified; BN = bulimia nervosa